ATE480553T1 - Replikin-peptide und anwendungen - Google Patents

Replikin-peptide und anwendungen

Info

Publication number
ATE480553T1
ATE480553T1 AT04785929T AT04785929T ATE480553T1 AT E480553 T1 ATE480553 T1 AT E480553T1 AT 04785929 T AT04785929 T AT 04785929T AT 04785929 T AT04785929 T AT 04785929T AT E480553 T1 ATE480553 T1 AT E480553T1
Authority
AT
Austria
Prior art keywords
peptides
replicin
applications
diagnosing
preventing
Prior art date
Application number
AT04785929T
Other languages
English (en)
Inventor
Samuel Bogoch
Elenore Bogoch
Original Assignee
Samuel Bogoch
Bogoch Elenore S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Bogoch, Bogoch Elenore S filed Critical Samuel Bogoch
Application granted granted Critical
Publication of ATE480553T1 publication Critical patent/ATE480553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04785929T 2003-06-06 2004-06-07 Replikin-peptide und anwendungen ATE480553T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47618603P 2003-06-06 2003-06-06
US50495803P 2003-09-23 2003-09-23
US53168603P 2003-12-23 2003-12-23
US10/860,050 US7442761B2 (en) 2003-06-06 2004-06-04 Replikin peptides and uses thereof
PCT/US2004/017936 WO2005010032A2 (en) 2003-06-06 2004-06-07 Replikin peptides and uses thereof

Publications (1)

Publication Number Publication Date
ATE480553T1 true ATE480553T1 (de) 2010-09-15

Family

ID=34109088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04785929T ATE480553T1 (de) 2003-06-06 2004-06-07 Replikin-peptide und anwendungen

Country Status (11)

Country Link
US (2) US7442761B2 (de)
EP (3) EP1636254B1 (de)
JP (1) JP2007526222A (de)
AT (1) ATE480553T1 (de)
AU (2) AU2004259640B2 (de)
CA (1) CA2528440A1 (de)
DE (1) DE602004029034D1 (de)
IL (3) IL172396A (de)
NZ (1) NZ544277A (de)
SG (1) SG182000A1 (de)
WO (1) WO2005010032A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592340A (en) * 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
EP2261377B1 (de) * 2003-11-04 2013-10-02 The Administrators Of The Tulane Educational Fund Verfahren zur Verhinderung der Viruszellenfusion durch Verhinderung der Funktion des Fusionstartbereichs von RNA-Viren mit Klasse I membranfusogenen Hüllproteinen
US9254315B2 (en) * 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
SG160327A1 (en) * 2005-02-16 2010-04-29 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
EP2003198A2 (de) * 2006-03-13 2008-12-17 Keio University Peptid zur hemmung einer grippeinfektion, inhibitor der grippeinfektion, liposom und prophylaktisches/therapeutisches mittel gegen grippe
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008060702A2 (en) * 2006-05-30 2008-05-22 Samuel Bogoch Replikin peptides and uses thereof
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
JP2011516027A (ja) * 2007-01-18 2011-05-26 ボゴーク，サミュエル レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法
CA2689181A1 (en) * 2007-05-30 2008-12-24 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2734226A2 (de) 2011-07-20 2014-05-28 Samuel Bogoch Gemeinsame peptides von letalen karzinomen und therapeutische zusammensetzungen mit diesen peptiden
WO2013151662A2 (en) 2012-03-09 2013-10-10 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus
ES2710321A1 (es) * 2017-10-20 2019-04-24 Consejo Superior Investigacion Adn polimerasas independientes de cebador y su uso para la sintesis de adn
CN111999508A (zh) * 2020-05-15 2020-11-27 上海交通大学 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
EP0221748A3 (de) 1985-11-01 1988-10-12 Samuel Dr. Bogoch Verfahren zur Herstellung von menschlichen Antikörpern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5231167A (en) 1989-09-08 1993-07-27 The Regents Of The University Of California Immunoglobulin-binding polypeptides
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6242578B1 (en) 1994-02-17 2001-06-05 Samuel Bogoch Aglyco products and methods of use
DE69534325T2 (de) 1995-04-11 2006-04-20 Bogoch, Samuel, Dr. Peptide zur behandlung von krebs
US6023659A (en) 1996-10-10 2000-02-08 Incyte Pharmaceuticals, Inc. Database system employing protein function hierarchies for viewing biomolecular sequence data
US6582703B2 (en) * 1996-11-26 2003-06-24 Bio Merieux Isolated nucleotide sequences associated with multiple sclerosis or rheumatoid arthritis and a process of detecting
US6070126A (en) 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
JPH11232291A (ja) 1998-02-16 1999-08-27 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質立体構造データベース検索方法
IT1300059B1 (it) 1998-04-24 2000-04-05 Ist Naz Ric Sul Cancro Peptidi ad attivita' chemiotattica e anti-hiv
US7176275B2 (en) 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
US6175830B1 (en) 1999-05-20 2001-01-16 Evresearch, Ltd. Information management, retrieval and display system and associated method
AU6097100A (en) 1999-07-13 2001-01-30 Regents Of The University Of Michigan, The Crosslinked dna condensate compositions and gene delivery methods
US6470277B1 (en) 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7452963B2 (en) 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
CA2441540A1 (en) 2001-03-27 2002-10-31 Samuel Bogoch Replikin peptides and uses thereof
US7420028B2 (en) 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
EP1414848B1 (de) 2001-07-09 2011-12-21 Samuel Dr. Bogoch Replikin-peptide und ihre verwendungszwecke
US7267942B2 (en) * 2003-03-24 2007-09-11 The University Of Hong Kong Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
EP2671129B1 (de) 2010-12-02 2016-03-09 SeeScan, Inc. Magnetisch erfassende benutzerschnittstellen-vorrichtungen und -geräte

Also Published As

Publication number Publication date
AU2010200602B2 (en) 2012-12-20
IL204266A (en) 2012-12-31
SG182000A1 (en) 2012-07-30
WO2005010032A2 (en) 2005-02-03
IL172396A0 (en) 2006-04-10
EP2338901A1 (de) 2011-06-29
CA2528440A1 (en) 2005-02-03
JP2007526222A (ja) 2007-09-13
AU2004259640A1 (en) 2005-02-03
EP2292643B1 (de) 2015-02-18
EP1636254A2 (de) 2006-03-22
IL199527A (en) 2013-02-28
EP1636254B1 (de) 2010-09-08
AU2010200602A1 (en) 2010-03-11
US7442761B2 (en) 2008-10-28
NZ544277A (en) 2009-02-28
DE602004029034D1 (de) 2010-10-21
US20090053257A1 (en) 2009-02-26
AU2004259640B2 (en) 2010-04-01
WO2005010032A3 (en) 2005-06-09
IL172396A (en) 2013-01-31
EP2292643A1 (de) 2011-03-09
US20050202415A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
ATE480553T1 (de) Replikin-peptide und anwendungen
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
DE602004023503D1 (de) Medizinisches behandlungswerkzeug und dieses entha
DE502004006293D1 (de) Chirurgisches Instrument, bei welchem Bewegungen des Instrumentskopfs und des Effektors entkoppelt sind
DOP2002000429A (es) Imidazotriazinas
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE60106151D1 (de) Additionshärtbare Silikonelastomermischungen, ihre Herstellung und Verwendung
DE602006002982D1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
IS2482B (is) Arómatísk súlfón og læknisfræðileg notkun þeirra
BR0313611A (pt) Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica
WO2003005880A3 (en) Replikin peptides and uses thereof
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE60220833D1 (de) Desinfektionsmittel für medizinische geräte und oberflächenanwendungen
ATE399532T1 (de) Medizinische seife
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE554109T1 (de) Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür
ATE538133T1 (de) Replikin-peptide und ihre verwendungszwecke
ATE319716T1 (de) Mikanolid-derivate, ihre herstellung und ihr gebrauch für therapeutische anwendungen
BR0209400A (pt) Composição para cuidado de tecido, processo para o tratamento de tecido, e, uso de uma composição
ATE424196T1 (de) Pharmazeutische zusammensetzungen mit platin- komplexen mit sekundären xanthaten und ihre therapeutischen anwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties